ALIMERA SCIENCES, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 12 rows in 2020. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2020-06-18: Reporting owner Kong Garheng; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-06-18: Reporting owner Halak Brian K; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-06-18: Reporting owner Myers C. Daniel; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2020-06-18: Reporting owner Snisarenko John; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2020-06-18 | Kong Garheng Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,333 3,333 owned after | $6.70 exercise price | 2020-06-22 | |
| 2020-06-18 | Halak Brian K Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,333 3,333 owned after | $6.70 exercise price | 2020-06-22 | |
| 2020-06-18 | Myers C. Daniel Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,333 3,333 owned after | $6.70 exercise price | 2020-06-22 | |
| 2020-06-18 | Snisarenko John Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,333 3,333 owned after | $6.70 exercise price | 2020-06-22 | |
| 2020-06-18 | Largent James R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,333 3,333 owned after | $6.70 exercise price | 2020-06-22 | |
| 2020-06-18 | Pizzo Peter J. III Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,333 3,333 owned after | $6.70 exercise price | 2020-06-22 | |
| 2020-06-18 | Szela Mary T Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,333 3,333 owned after | $6.70 exercise price | 2020-06-22 | |
| 2020-01-10 | Jones John Philip Officer (Chief Financial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,000 19,000 owned after | $6.75 exercise price | 2020-01-14 | |
| 2020-01-10 | Holland David Officer (Chief Marketing Officer & SVP) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +14,000 14,000 owned after | $6.75 exercise price | 2020-01-14 | |
| 2020-01-10 | Kaba Samer Officer (Chief Medical Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,500 17,500 owned after | $6.75 exercise price | 2020-01-14 | |
| 2020-01-10 | Ashman Philip Officer (Chief Operating Officer & SVP) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $6.75 exercise price | 2020-01-14 | |
| 2020-01-10 | EISWIRTH RICHARD S JR Director, Officer (President and CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +53,500 53,500 owned after | $6.75 exercise price | 2020-01-14 |